A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Hepatocellular Carcinoma Clinical Trial

Official title:

A Single Group, Open Label, Multi-center Clinical Study to Assess the Efficacy and Safety of Anlotinib in HCC Patients at High Risk of Post Surgery Recurrence.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03945799
• Other study ID #: KY2019-AHR-ZJU
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: April 22, 2019
• Est. completion date: June 25, 2022

Study information

• Verified date: August 2022
• Source: Zhejiang University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence.

Description:

Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Recurrence of HCC is still a great challenge and threat to the patients after resection surgery. Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. HCC patients who meet the eligibility criteria of this clinical trial will be administrated Anlotinib 12mg QD PO d1-14, 21 days per cycle. The disease free survival (DFS), overall survival (OS) and any adverse effect during the 8 cycles of Anlotinib treatment will be evaluated in order to assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 28
• Est. completion date: June 25, 2022
• Est. primary completion date: June 25, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• No allergic history of Anlotinib

• 18-75 years

• No history of severe arrhythmia or heart failure

• No history of severe ventilation dysfunction or severe pulmonary infection

• No acute or chronic renal failure, creatinine clearance > 40 mL/min

• Liver function is normal: child-pugh grade A or grade B (=7 points), total bilirubin = 3.0 mg/dL, albumin = 28 g/L, AST, ALT, ALP= 5 times of the upper limit of normal value

• Blood test: the absolute neutrophil count = 1.5×10^9 /L, Hb = 8.5 g/L, PLT = 75×10^9 /L (without blood transfusions and drug therapy 14 days before the screening)

• Blood coagulation function: INR=2.3

• ECOG: 0-2

• Pathology: hepatocellular carcinoma

• Satisfy any of the following:

A. portal vein, hepatic vein or bile duct carcinoma thrombus B. microvascular invasion (MVI) grade II (> 5 MVI, or MVI occurs in the area more than 1 cm from the tumor) C. tumor number = 3 D. preoperative rupture of tumor or tumor invasion adjacent organs

• Patients participate in the study voluntarily and sign informed consent

Exclusion Criteria:

• Pregnant or lactating women

• Patients who have had or are currently complicated with other malignant tumors

• Recurrent hepatocellular carcinoma

• Patients who participated in other clinical trials within 1 month

• Patients with mental illness

• Patients treated with targeted drugs, immunotherapy (such as PD1 antibody), FOLFOX systemic chemotherapy or huaier granules after surgery

• Urine protein = ++,and 24-hour urinary protein excretion>1.0 g confirmed

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma
• Recurrence

Intervention

Drug:
• Anlotinib Hydrochloride
Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Medical School of Zhejiang University	Hangzhou	Zhejiang

Sponsors (9)

Lead Sponsor	Collaborator
Zhejiang University	Huashan Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shulan Hospital of Hangzhou, The First Affiliated Hospital of Zhengzhou University, The First Hospital of Jilin University, Third Affiliated Hospital, Sun Yat-Sen University, Tianjin First Central Hospital, West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease free survival	The period from resection surgery to recurrence of HCC	From randomization to recurrence of HCC or death (up to 1year)
Secondary	Adverse effect	Any adverse effects occur during the use of anlotinib	Up to 1year
Secondary	Overall survival	The survival rate in a year	1 year